- TUTORIALIBECCME
-
Author(s)/Faculty: Leonard H. Calabrese, DO; Jonathan Kay, MD; Gregg J. Silverman, MD Source: Type: Monograph Articles/Items: 6 Release Date: 9/15/2015 Expiration Date: 9/15/2016 Credit Type: CME Number of Credit(s): 1 Cost: Free CME Provider: - Rheumatoid arthritis (RA) is an autoimmune disease characterized by a dysregulation of inflammatory processes leading to progressive joint destruction, systemic inflammation, and extra-articular manifestations. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as efficacy profiles of current and emerging disease modifying antirheumatic drugs (DMARDs). This monograph integrates a discussion between the basic and clinical immunologic sciences to give learners a better understanding of autoimmunity, treatment-associated immunogenicity, and the development of biosimilars for RA management.
- This activity is supported by an educational grant from Bristol-Myers Squibb.
Support Statement: This activity is supported by an educational grant from Bristol-Myers Squibb.
Target Audience: The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with rheumatoid arthritis (RA).
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Assess B-cell biology and its role in immune-mediated inflammatory diseases, including rheumatoid arthritis.
- Define immunogenicity in the context of biologic therapies and appraise its role in efficacy and toxicity.
- Apply clinical advances in the use of biologic therapy to optimize the treatment of rheumatoid arthritis.
Activity Chair:
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Theodore F. Classen DO Chair of Osteopathic Research and Education
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland, OH
Faculty:
Jonathan Kay, MD
Professor of Medicine
University of Massachusetts Medical School
Director of Clinical Research,Division of Rheumatology
University of Massachusetts Medical School
Worcester, MA
Gregg J. Silverman, MD
Professor of Medicine and Pathology
Director, Laboratory of B-Cell Immunology
NYU Langone Medical Center
New York, NY
External Reviewer:
Kevin D. Deane, MD, PhD
This enduring material is approved for 1 year from the date of original release, Septmber 15, 2015, to September 15, 2016.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty reports the following relationship(s):
Leonard H. Calabrese, DO
Consulting Fee: AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech
Jonathan Kay, MD
Consulting Fees: AbbVie, Alexion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Crescendo Bioscience, Inc., Eli Lilly, Epirus Biopharmaceuticals, Genentech, Hospira, Janssen, Merck, Nippon Kayaku, Novartis, PanGenetics, Pfizer, Samsung Bioepis, Roche, UCB
Contracted Research (paid directly to institution): AbbVie, Ardea Biosciences, Eli Lilly, Pfizer, Roche
Gregg J. Silverman, MD
Consulting Fees: Celgene, GlaxoSmithKline, Quest, Pfizer
Speakers Bureau: Roche
External Reviewer reports the following relationship(s):
Kevin D. Deane, MD, PhD
No relevant financial relationships to disclose.
Medical Writer reports the following relationship(s):
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.